Bullet point summary
What is already known
- Amlexanox attenuates cardiomyocyte hypertrophy and regulates
anti-inflammatory responses
- Forskolin induces ACs-cAMP-dependent immunoregulation besides
facilitating cardiac contractions
What this study adds
- Amlexanox or Forskolin single therapies do not exhibit much potency in
adaptive immunoregulation, preservation of cardiac function
- The synergy of Amlexanox and Forskolin keeps the heart healthy and
functional during CCS
Clinical significance
Amlexanox and Forskolin combination therapy may be a potential
intervention for PCH prevention